CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
|Articles|June 8, 2011
- Pharmaceutical Commerce - May/June 2011
HDMA honors AmerisoureBergen's Yost with Nexus Award
AmerisourceBergen CEO has had a 37-year career in healthcare distribution
Advertisement
At HDMA’s annual Business & Leadership Conference this week, HDMA’s research arm, the Center for Healthcare Supply Chain Research, and its industry sponsor, Genentech, Inc., honored Yost with the 2011 Nexus Award for Lifetime Achievement. The award recognizes leadership in the healthcare industry and HDMA, as well as community involvement and professional accomplishment.
R. David Yost, has been CEO of AmerisourceBergen since its origin in the merger of AmeriSource Health and Bergen Brunswig Corp. in 2001. He started in the industry in 1974 as a salesman at a predecessor company to AmeriSource, eventually rising to chairman and CEO of AmeriSource. AmerisourceBergen is today a $78-billion company, No. 27 on the Fortune 500. Yost is also on the board of directors of the International Federation of Pharmaceutical Wholesalers, Tyco Corp., the Board of Trustees of Penn Medicine, and a founding director of the United States Air Force Academy Endowment Board. He is a graduate of the Air Force Academy, and has an MBA from UCLA.
“Dave embodies all of the attributes of the Nexus Award through his industry and community leadership,” said HDMA President and CEO John M. Gray. “Throughout his distinguished career he has been a tireless champion for distributors and the customers they serve, yet through all his success and accomplishment, has remained humble and dedicated to his family and community.”
Articles in this issue
about 15 years ago
Introabout 15 years ago
What Makes a Pharmaceutical Industry Leader?about 15 years ago
How REMS Affect Pharmaceutical Distribution Processes and Partnersabout 15 years ago
Patient-Administered Therapies Drive New Delivery System Designsover 15 years ago
For a Lucky Few, Biopharma Expansion a Reality Againover 15 years ago
Making Pallets a Supply Chain Asset Instead of an Unrecoverable CostAdvertisement
Related to this article
Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Rebate Timing Distorts a Pharmacy's 340B Books
2
EU Pharma Reform: Strategic Implications for US Drugmakers
3
White House Extends MFN Pricing to Every State Medicaid Program
4
CPHI Milan Leadership Summit Returns With Supply Chain Focus
5